LitAlert ~~ GeneLit.com

    • Hereditary Breast Cancer in the Brazilian State of Ceará (The CHANCE Cohort): Higher-than-expected prevalence of recurrent germline pathogenic variants.
    • Gifoni ACL, Palmero EI, Wotroba CM, Gifoni MA, Achatz MI, dos Santos W.
    • Front Oncol. 2022 Jun 20;12:932957. doi: 10.3389/fonc.2022.932957.
    • Cost-effectiveness of BRCA 1/2 genetic test and preventive strategies using real-world data from an upper-middle income country.
    • Lourenção M, Correa Galendi JS, HD, Antoniazzi AP, Grasel R, Carvalho AL, Mauad EC, Oliveira JH, Reis RM, Mandrik O, Palmero EI.
    • Front Oncol. 2022 Jun 20;12:951310. doi: 10.3389/fonc.2022.951310.
    • Stress, Anxiety, and Health-Related Quality of Life in BRCA1/2-Positive Women with and without Cancer: A Comparison of Four US Female Samples.
    • Dibble KE, Donorfio LKM, Britner PA, Bellizzi KM.
    • Gynecol Oncol Rep. 2022 Jun 20;101033. doi: 10.1016/j.gore.2022.101033.
    • Chemotherapy Regimens Received by Women with BRCA1/2 Pathogenic Variants for Early-Stage Breast Cancer Treatment.
    • Kurian AW, Abrahamse P, Hamilton AS, Caswell-Jin JL, Gomez SL, Hofer TJ, Ward KC, Katz SJ.
    • JNCI Cancer Spectr. 2022 Jun 20:pkac045. doi: 10.1093/jncics/pkac045. Epub ahead of print.
    • Mutations in exon 11 (11.1 and 11.2) of the BRCA1 gene and risk factors for breast cancer in Burkina Faso.
    • Kiendrebeogo IT, Zoure AA, Zongo FI, Ouattara AK, Ouedraogo MNL, Amegnona J, Yonli AT, Bayala B, Zongo N, Bambara AH, Sawadogo AY, Zohoncon TM, Obiri-Yeboah D, Simpore J.
    • J Public Health Afr. 2022 May 25;13(1):1921. doi: 10.4081/jphia.2022.1921.
    • Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer.
    • Xiao Y, Gao W.
    • Oncol Lett. 2022 May 19;24(1):219. doi: 10.3892/ol.2022.13340.